General Information of Drug (ID: DME18UM)

Drug Name
MER-102 Drug Info
Indication
Disease Entry ICD 11 Status REF
Thrombosis DB61-GB90 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DME18UM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Antithrombin-III (ATIII)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ardeparin DMYRX8B Deep vein thrombosis BD71 Approved [3]
Heparin Calcium DMEVXY6 Coagulation defect 3B10.0 Approved [3]
Sulodexide DMNUC42 Tinnitus MC41 Approved [4]
Heparin Sodium DM9KHZL Coagulation defect 3B10.0 Approved [5]
Unfractionated heparin DMCWM03 Thrombosis DB61-GB90 Phase 3 [6]
Heparin low molecular weight DMGFULM Thrombosis DB61-GB90 Phase 3 [7]
KW-3357 DMP3GI2 Coagulation defect 3B10.0 Phase 3 [8]
O-desulfated heparin DMJL4A7 Chronic obstructive pulmonary disease CA22 Phase 2 [9]
M118 DML0I2Z Acute coronary syndrome BA41 Phase 2 [10]
PMX-60056 DMWT73D Coagulation defect 3B10.0 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Antithrombin-III (ATIII) TT4QPUL ANT3_HUMAN Inhibitor [2]

References

1 Fondaparinux sodium. Drugs Today (Barc). 2002 Mar;38(3):185-94.
2 Clinical pipeline report, company report or official report of Merrion's GIPET technology.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632).
6 Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thromb Res. 1982 Nov 15;28(4):487-97.
7 Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits. Thromb Res. 1995 Dec 1;80(5):391-8.
8 Company report (kyowa-kirin)
9 Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest. 1981 Jan;67(1):223-8.
10 Clinical pipeline report, company report or official report of Momentapharma.
11 Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Correction in: Chest. 2013 August; 144(2): 721.